Evidence map›Paper›PMID 40308032›Full record

ArticleJournal of cachexia, sarcopenia and muscle2025

Integrated Multiomics Analyses of the Molecular Landscape of Sarcopenia in Alcohol-Related Liver Disease.

Nicole Welch, Pugazhendhi Kannan, Saurabh Mishra, Annette Bellar, Vandana Agrawal, Grahame Kidd, Emily Benson, Ryan Musich, Raya Tabbalat, Ling Li and 5 more

Abstract read
In one paragraph

Article in Journal of cachexia, sarcopenia and muscle, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed.

  1. Review
  2. Bioimpedance Analysis to Predict Clinical Outcomes of Liver Cirrhosis in a Prospective Cohort Study.JGH open : an open access journal of gastroenterology and hepatology · 2026
    Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Nicole WelchDepartments of Gastroenterology and Hepatology, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA.
Pugazhendhi KannanDepartments of Inflammation and Immunity, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA.
Saurabh MishraDepartments of Inflammation and Immunity, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA.
Annette BellarDepartments of Inflammation and Immunity, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA.
Vandana AgrawalDepartments of Inflammation and Immunity, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA.
Grahame Kidd3D EM Ultrastructural Imaging and Computation Core, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA.
Emily Benson3D EM Ultrastructural Imaging and Computation Core, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA.
Ryan MusichDepartments of Inflammation and Immunity, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA.
Raya TabbalatDepartments of Inflammation and Immunity, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA.
Ling LiDepartments of Proteomics Core, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA.
J Mark BrownDepartments of Cancer Biology, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA.
Belinda WillardDepartments of Proteomics Core, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA.
Karyn A EsserDepartment of Physiology and Aging, University of Florida, Gainesville, Florida, USA.
Laura E NagyDepartments of Inflammation and Immunity, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA.
Srinivasan DasarathyDepartments of Gastroenterology and Hepatology, Cleveland Clinic, Lerner Research Institute, Cleveland, Ohio, USA.ORCID 0000-0003-1774-0104

Funding

Project Two - Exercise Training Decreases Alcohol Drinking by an FGF21-Dependent MechanismP50AA024333 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy · 2016 to 2026
$19.6M
The Cleveland Digestive Diseases Research Core Center (DDRCC)P30DK097948 · NIDDK · CASE WESTERN RESERVE UNIVERSITY · PI Fabio Cominelli · 2015 to 2026
$15.6M
VCU-Atlanta Center for the Childhood Liver Disease Research Network (ChiLDReN)U01DK062470 · NIDDK · VIRGINIA COMMONWEALTH UNIVERSITY · PI SAUL J. KARPEN · 2005 to 2026
$12.7M
Non Alcoholic Steatohepatitis Clinical Research NetworkU01DK061732 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy · 2002 to 2026
$12.2M
Biomedical Data Commons Workbench (BDCW)OT2OD030544 · OD · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI SUBRAMANIAM, SHANKAR · 2020 to 2024
$3.2M
Integrated Therapies for Alcohol use in Alcohol-associated Liver Disease (ITAALD)- Cleveland Clinic Clinical CenterU01AA026976 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI Srinivasan Dasarathy, David Streem · 2018 to 2026
$3.2M
Sarcopenia in cirrhosis is mediated by a hyperammonemic stress responseR01DK113196 · NIDDK · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN, HATZOGLOU, MARIA · 2018 to 2021
$2.3M
Novel therapeutics for alcoholic hepatitis - Cleveland Translational ComponentU01AA021890 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI NAGY, LAURA E. · 2012 to 2017
$1.6M
Mechanisms of Malnutrition in Cirrhosis with Portosystemic ShuntingR01GM119174 · NIGMS · CLEVELAND CLINIC LERNER COM-CWRU · PI DASARATHY, SRINIVASAN · 2017 to 2020
$1.2M
Mechanisms of HIF1 alpha mediated dysregulated skeletal muscle proteostasis in alcoholic liver diseaseK08AA028794 · NIAAA · CLEVELAND CLINIC LERNER COM-CWRU · PI WELCH, NICOLE · 2021 to 2025
$896k
High-End Instrumentation (HEI) Grant Program (S10)S10OD023436 · OD · CLEVELAND CLINIC LERNER COM-CWRU · PI WILLARD, BELINDA BELLE · 2017 to 2017
$873k
Nutritional modulation to minimize resistance exercise induced metabolic deregulations and improve training responsiveness in Chronic Obstructive Pulmonary DiseaseR56HL141744 · NHLBI · TEXAS A&M UNIVERSITY · PI DEUTZ, NICOLAAS E, ENGELEN, MARIELLE PKJ · 2019 to 2019
$757k
American College of Gastroenterology Clinical Research AwardNational Institutes of Health, United States 1S10OD023436National Institutes of Health, United States 3U01AA026976-03S1National Institutes of Health, United States 5U01DK062470-17S2National Institutes of Health, United States NIH K08 AA028794National Institutes of Health, United States OT2-OD030544National Institutes of Health, United States R01 AA021890National Institutes of Health, United States R21 AR 071046National Institutes of Health, United States R56HL141744National Institutes of Health, United States S10OD030398National Institutes of Health, United States U01 AA 026976National Institutes of Health, United States U2C-DK119886NHLBI NIH HHS R56 HL141744NIAAA NIH HHS K08 AA028794NIAAA NIH HHS P50 AA024333NIAAA NIH HHS U01 AA021890NIAAA NIH HHS U01 AA026976NIAMS NIH HHS R21 AR071046NIDDK NIH HHS P30 DK097948NIDDK NIH HHS R01 DK113196NIDDK NIH HHS U01 DK061732NIDDK NIH HHS U01 DK062470NIGMS NIH HHS R01 GM119174NIH HHS OT2 OD030544NIH HHS S10 OD023436NIH HHS S10 OD030398
6 · The paper itself

Abstract

backgroundSkeletal muscle is a major target for ethanol-induced perturbations, leading to sarcopenia in alcohol-related liver disease (ALD). The complex interactions and pathways involved in adaptive and maladaptive responses to ethanol in skeletal muscle are not well understood. Unlike hypothesis-driven experiments, an integrated multiomics-experimental validation approach provides a comprehensive view of these interactions.

methodsWe performed multiomics analyses with experimental validation to identify novel regulatory mechanisms of sarcopenia in ALD. Studies were done in a comprehensive array of models including ethanol-treated (ET) murine and human-induced pluripotent stem cell-derived myotubes (hiPSCm), skeletal muscle from a mouse model of ALD (mALD) and human patients with alcohol-related cirrhosis and controls. We generated 13 untargeted datasets, including chromatin accessibility (assay for transposase accessible chromatin), RNA sequencing, proteomics, phosphoproteomics, acetylomics and metabolomics, and conducted integrated multiomics analyses using UpSet plots and feature extraction. Key findings were validated using immunoblots, redox measurements (NAD

resultsMultiomics analyses revealed enrichment in mitochondrial oxidative function, protein synthesis and senescence pathways consistent with the known effects of hypoxia-inducible factor 1α (HIF1α) during normoxia. Across preclinical and clinical models, HIF1α targets (n = 32 genes) and signalling genes (n > 100 genes) (n = 3 ATACseq, n = 65 phosphoproteomics, n = 10 acetylomics, n = 6 C2C12 proteomics, n = 106 C2C12 RNAseq, n = 64 hiPSC RNAseq, n = 30 hiPSC proteomics, n = 3 mouse proteomics, n = 25 mouse RNAseq, n = 8 human RNAseq, n = 3 human proteomics) were increased. Stabilization of HIF1α (C2C12, 6hEtOH 0.24 ± 0.09; p = 0.043; mALD 0.32 ± 0.074; p = 0.005; data shown as mean difference ± standard error mean) was accompanied by enrichment in the early transient and late change clusters, -log(p-value) = 1.5-3.8, of the HIF1α signalling pathway. Redox ratio was reduced in ET myotubes (C2C12: 15512 ± 872.1, p < 0.001) and mALD muscle, with decreased expression of electron transport chain components (CI-V, p < 0.05) and Sirt3 (C2C12: 0.067 ± 0.023, p = 0.025; mALD: 0.41 ± 0.12, p = 0.013). Acetylation of mitochondrial proteins was increased in both models (C2C12: 107364 ± 4558, p = 0.03; mALD: 40036 ± 18 987, p = 0.049). Ethanol-induced SAMP was observed across models (P16: C2C12: 0.2845 ± 0.1145, p < 0.05; hiPSCm: 0.2591, p = 0.041). MitoLbNOX treatment reversed redox imbalance, HIF1α stabilization, global acetylation and myostatin expression (p < 0.05).

conclusionsAn integrated multiomics approach, combined with experimental validation, identifies HIF1α stabilization and accelerated post-mitotic senescence as novel mechanisms of sarcopenia in ALD. These findings show the complex molecular interactions leading to mitochondrial dysfunction and progressive sarcopenia in ALD.

Indexed as

SarcopeniaAnimalsDisease Models, AnimalHumansMaleMetabolomicsMiceMultiomicsMuscle, SkeletalProteomicsalcohol‐related liver diseasehypoxia‐inducible factor‐1‐alphamitochondrial oxidative dysfunctionprotein acetylationredox ratiosarcopeniasenescencesirtuins

Identifiers

PMID40308032
PMCPMC12044136

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.